Current National Prevalence of Diagnosed A-Fib, 10.55 Million
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 18, 2024 -- The prevalence of diagnosed atrial fibrillation (AF) in the United States is 4.48 percent among the adult population, according to a study published online Sept. 13 in the Journal of the American College of Cardiology.
Jean Jacques Noubiap, M.D., Ph.D., from the University of California-San Francisco, and colleagues determined the contemporary age-, sex-, and race-standardized prevalence and the number of adults with diagnosed AF in the United States. A cohort of adults aged 20 years and older who received hospital-based care in California from 2005 to 2019 was assembled; AF and other comorbidities were identified using the International Classification of Diseases codes. The U.S. census was utilized to calculate the national estimates of diagnosed AF.
Overall, 6.8 percent of the 29,250,310 patients had an AF diagnosis. The researchers found an increase in the proportion of patients with diagnosed AF, from 4.49 percent in 2005-2009 to 6.82 percent in 2015-2019. AF patients became relatively younger over time, and they were less likely to be female or White and more likely to have hypertension and diabetes. The current standardized national prevalence of diagnosed AF is at least 10.55 million, comprising 4.48 percent of the adult population.
"Given the adverse consequences and considerable health care utilization associated with the disease, this rising prevalence calls for greater resource allocation and more efficient prevention and treatment strategies to curb the increasing burden of AF in the United States," the authors write.
One author disclosed ties to InCarda.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-09-19 06:00
Read more
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with Keytruda (pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
- ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
- American College of Gastroenterology, Oct. 25-30
- Female Pediatricians Earn About 93 Percent of Male Pediatricians
- Bloated After That Holiday Meal? What's Normal, What's Not
- Shorla Oncology Announces U.S. FDA Expanded Approval of Jylamvo (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions